BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100 at HonorHealth Research Institute
First-in-Human Trial to Enroll Up to 24 Patients with Refractory Solid Tumors MOUNTAIN VIEW, Calif., Jan. 19, 2021 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the initiation of patient enrollment at the HonorHealth Research Institute in Scottsdale, Ariz. for a Phase 1 dose-escalation trial to...